Substances used to lower plasma CHOLESTEROL levels.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Sequential operating programs and data which instruct the functioning of a digital computer.
The portion of an interactive computer program that issues messages to and receives commands from a user.
Individual's rights to obtain and use information collected or generated by others.
Available manpower, facilities, revenue, equipment, and supplies to produce requisite health care and services.
A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
A publication issued at stated, more or less regular, intervals.
A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.
Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
Distensibility measure of a chamber such as the lungs (LUNG COMPLIANCE) or bladder. Compliance is expressed as a change in volume per unit change in pressure.
Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
Voluntary cooperation of the patient in following a prescribed regimen.
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Pathological processes of the LIVER.
Tumors or cancer of the LIVER.
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
A characteristic symptom complex.
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
The veins and arteries of the HEART.
Cell surface receptors which bind prostaglandins with a high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin E receptors prefer prostaglandin E2 to other endogenous prostaglandins. They are subdivided into EP1, EP2, and EP3 types based on their effects and their pharmacology.
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
A subtype of prostaglandin E receptors that specifically couples to GS ALPHA GTP-BINDING PROTEIN SUBUNITS and subsequently activates ADENYLYL CYCLASES. The receptor may also signal through the activation of PHOSPHATIDYLINOSITOL 3-KINASE.
A subtype of prostaglandin E receptors that specifically couples to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI and subsequently inhibits ADENYLYL CYCLASES.
A subtype of prostaglandin E receptors that specifically couples to GTP-BINDING PROTEIN ALPHA SUBUNIT, GQ and the subsequently activates TYPE C PHOSPHOLIPASES. Additional evidence has shown that the receptor can act through a calcium-dependent signaling pathway.
A subtype of prostaglandin E receptors that specifically couples to GS ALPHA GTP-BINDING PROTEIN SUBUNITS and subsequently activates ADENYLYL CYCLASES.
Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.
Databases devoted to knowledge about specific genes and gene products.
The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.
A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms.

Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. (1/2109)

The hypocholesterolemic activities of pamaqueside and tiqueside, two structurally similar saponins, were evaluated in cholesterol-fed rabbits. The pharmacological profiles of the saponins were virtually identical: both dose-dependently decreased the intestinal absorption of labeled cholesterol 25-75%, increased fecal neutral sterol excretion up to 2.5-fold, and decreased hepatic cholesterol content 10-55%. High doses of pamaqueside (>5 mg/kg) or tiqueside (>125 mg/kg) completely prevented hypercholesterolemia. Decreases in plasma and hepatic cholesterol levels were strongly correlated with increased neutral sterol excretion. Ratios of neutral sterol excreted to pamaqueside administered were greater than 1:1 at all doses, in opposition to the formation of a stoichiometric complex previously suggested for tiqueside and other saponins. Ratios in tiqueside-treated rabbits were less than unity, a reflection of its lower potency. Pamaqueside-treated rabbits exhibited a more rapid decline in plasma cholesterol concentrations than control animals fed a cholesterol-free diet, indicating that the compound also inhibited the absorption of biliary cholesterol. Intravenous administration of pamaqueside had no effect on plasma cholesterol levels despite plasma levels twice those observed in rabbits given pamaqueside orally. These data indicate that pamaqueside and tiqueside induce hypocholesterolemia by blocking lumenal cholesterol absorption via a mechanism that apparently differs from the stoichiometric complexation of cholesterol hypothesized for other saponins.  (+info)

Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship. (2/2109)

Our understanding of the factors that regulate the secretion of apoB100 lipoproteins remains incomplete with considerable debate as to the role, if any, for cholesterol ester in this process. This study examines this issue in primary cultures of hamster hepatocytes, a species in which both cholesterol and apoB100 metabolism are very similar to man. Addition of oleate to medium increased the mass of triglyceride and cholesterol ester within the hepatocyte and also increased the secretion of triglycerides, cholesterol ester, and apoB100 into the medium. Next, the responses of hamster hepatocytes to addition of either an HMG-CoA reductase inhibitor (lovastatin) or an acyl-CoA cholesterol acyltransferase inhibitor (58-035) to the medium, with or without added oleate, were determined. Effects of either agent were only evident in the oleate-supplemented medium in which cholesterol ester mass had been increased above basal. If oleate was not added to the medium, neither agent reduced apoB100 secretion; equally important, over the 24-hour incubation, neither agent, at the concentration used, produced any detectable change in intracellular cholesterol ester mass. However, in contrast to the estimates of mass, which were unchanged, under the same conditions radioisotopic estimates of cholesterol ester synthesis were markedly reduced. Any conclusion as to the relation of cholesterol ester mass to apoB100 secretion would therefore depend on which of the 2 methods was used. Overall, the data indicate a close correlation between the mass of cholesterol ester within the hepatocyte and apoB100 secretion from it and they go far to explain previous apparently contradictory data as to this relation. More importantly, though, taken with other available data, they indicate that the primary response of the liver to increased delivery of lipid is increased secretion rather than decreased uptake. These results point, therefore, to a hierarchy of hepatic responses to increased flux of fatty acids and increased synthesis of cholesterol that in turn suggests a more dynamic model of cholesterol homeostasis in the liver than has been appreciated in the past.  (+info)

Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. (3/2109)

BACKGROUND: Full-fat sitostanol ester-containing margarine reduces serum total and LDL cholesterol, but the effect of plant stanol ester-containing margarine as part of a low-fat, low-cholesterol diet has not been studied. OBJECTIVE: We investigated the cholesterol-lowering effects of 2 novel, low-fat stanol ester-containing margarines as part of a low-fat diet recommended for hypercholesterolemic subjects. DESIGN: In a parallel, double-blind study, 55 hypercholesterolemic subjects were randomly assigned after a 4-wk high-fat diet (baseline) to 3 low-fat margarine groups: wood stanol ester-containing margarine (WSEM), vegetable oil stanol ester-containing margarine (VOSEM), and control margarine (no stanol esters). The groups consumed the margarines for 8 wk as part of a diet resembling that of the National Cholesterol Education Program's Step II diet. The daily mean total stanol intake was 2.31 and 2.16 g in the WSEM and VOSEM groups, respectively. RESULTS: During the experimental period, the reduction in serum total cholesterol was 10.6% (P < 0.001) and 8.1% (P < 0.05) greater and in LDL cholesterol was 13.7% (P < 0.01) and 8.6% (P = 0.072) greater in the WSEM and VOSEM groups, respectively, than in the control group. Serum campesterol concentrations decreased 34.5% and 41.3% (P < 0.001) in the WSEM and VOSEM groups, respectively. Serum HDL cholesterol, sitostanol, campestanol, beta-carotene, and fat-soluble vitamin concentrations did not change significantly from baseline. CONCLUSIONS: We conclude that the low-fat, plant stanol ester-containing margarines are effective cholesterol-lowering products in hypercholesterolemic subjects when used as part of a low-fat, low-cholesterol diet. They offer an additional, clinically significant reduction in serum cholesterol concentrations to that obtained with a low-fat diet alone.  (+info)

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. (4/2109)

BACKGROUND: Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone. AIMS: To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition. METHODS: Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period. RESULTS: Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04). CONCLUSIONS: Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.  (+info)

Effect of the hypocholesterolemic agent YM-16638 on cholesterol biosynthesis activity and apolipoprotein B secretion in HepG2 and monkey liver. (5/2109)

YM-16638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-++ +thiadiazol-2-yl] thio] acetic acid) showed a strong hypocholesterolemic effect in humans and monkeys. To clarify the mechanism of this hypocholesterolemic effect, the action of YM-16638 on cholesterol biosynthesis in the cultured human hepatoma cell line HepG2 and cynomolgus monkey liver was examined. Cholesterol biosynthesis activity derived from [14C]acetic acid, [3H/14C]mevalonic acid or [14C]isopentenyl pyrophosphate substrates was significantly decreased, but not that from [3H]farnesyl pyrophosphate or [3H]squalene substrates in HepG2 cells treated with YM-16638. Simultaneously, treatment of these cells with YM-16638 changed neither the rate of apolipoprotein B synthesis from [35S]methionine nor its secretion. In addition, the activities of hepatic cholesterol biosynthesis enzymes HMG-CoA reductase, mevalonate kinase (MK), isopentenyl pyrophosphate isomerase (IPPI), farnesyl pyrophosphate synthase (FPPS), squalene synthase and squalene epoxidase were measured in monkeys fed a diet supplemented with YM-16638. Among these enzymes, MK, IPPI and FPPS activities in the YM-16638-treated group significantly decreased by 38%, 56% and 30%, respectively, when compared to those from control animals receiving no drug treatment. These results indicate that YM-16638 has the characteristics of a cholesterol biosynthesis inhibitor.  (+info)

Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters. (6/2109)

The action of LY295427 [(3alpha,4alpha, 5alpha)-4-(2-propenylcholestan-3-ol)], a compound that derepresses low-density lipoprotein receptor (LDL-R) expression in a cell-based model, was examined in hamsters. It was found that the compound does not have an effect in normal chow-fed hamsters, in which LDL-R levels are not repressed, but exerts a marked hypocholesterolemic effect (>70% decrease) in cholesterol-coconut oil-fed hamsters, in which LDL-R is repressed. In this model, there is a dose-response for cholesterol lowering with an approximate ED50 value of 40 mg/kg/day and an inverse relationship between serum cholesterol and serum LY295427 levels. LDL-R mRNA is increased (2-fold) and liver cholesterol ester content is decreased (>90%). Unlike the 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor lovastatin, the decreased serum cholesterol is confined to the non-high-density lipoprotein fraction. Furthermore, LY295427 does not affect cholesterol biosynthesis, and it does not have a significant effect on cholesterol absorption. These data suggest that LY295427 acts in the hypercholesterolemic hamster by derepressing LDL-R transcription, thereby enhancing cholesterol clearance from the blood. The results with LY295427 suggest that compounds that act to increase LDL-R may represent a novel approach in the pharmacotherapy for hypercholesterolemia.  (+info)

Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. (7/2109)

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in cholesterol biosynthesis. HMG-CoA reductase converts HMG-CoA to mevalonate, which is then converted into cholesterol or various isoprenoids through multiple enzymatic steps. In this study, we examined the cytotoxic effects of lovastatin, an HMG-CoA reductase inhibitor, in C6 glial cells. Lovastatin at concentrations higher than 10 microM suppressed cell proliferation and induced cell death, which were prevented completely by mevalonate (300 microM). The data from lactate dehydrogenase assay and fluorescence microscopic assay using Hoechst 33342 and propidium iodide showed that mevalonate at a concentration of 100 microM could prevent lovastatin-induced cell death, whereas it could not prevent lovastatin-induced inhibition of cell proliferation. These data suggest that the lovastatin-induced interruption of cell cycle transition was not sufficient to induce cell death in C6 glial cells. In the presence of lovastatin at concentrations higher than 10 microM, DNA laddering, the typical finding of apoptosis, was identified. Lovastatin-induced apoptosis was prevented by mevalonate (100 microM). Both cycloheximide (0.5 microgram/ml) and actinomycin D (0.1 microgram/ml) prevented lovastatin-induced DNA laddering. In this study, we demonstrated that the cytotoxic effects of lovastatin fall into two categories: suppression of cell growth and induction of apoptosis in C6 glial cells.  (+info)

The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. (8/2109)

OBJECTIVES: The purpose of the study was to assess the effect of lipid reduction with pravastatin on hospital admissions in middle-aged men with hypercholesterolemia in the West of Scotland Coronary Prevention Study. BACKGROUND: A prospective, randomized controlled trial was undertaken in primary care centers in the West of Scotland. METHODS: A total of 6,595 participants randomized to receive pravastatin 40 mg or placebo daily were followed up for a mean of 4.9 years (range 3.5 to 6.1 years). Analysis of hospital admissions was undertaken according to the "intention to treat" principle both for cardiovascular diseases and noncardiovascular diseases (including malignant neoplasms, psychiatric diagnoses, trauma and other causes). A secondary analysis of hospitalization in patients who were > or = 75% compliant was performed. RESULTS: During the trial, 2,198 (33%) of the 6,595 men were admitted to hospital on 4,333 occasions, of which 1,234 (28%) were for cardiovascular causes. Pravastatin reduced the number of subjects requiring hospital admission for cardiovascular causes by 21% (95% CI [confidence interval] 9 to 31, p = 0.0008) overall, and by 27% (95% CI 15 to 38) in compliant participants. The number of admissions per 1,000 subject-years for cardiovascular disease was reduced by 10.8 (95% CI 4 to 17.4, p = 0.0013) in all subjects, and by 15.6 (95% CI 8.3 to 23, p < 0.0001) in compliant participants. Pravastatin had no significant influence on hospital admission for any noncardiovascular diagnostic category. There were 13.4 fewer admissions per 1,000 subject-years for all causes in the pravastatin-treated group (95% CI -0.4 to 27.3, p = 0.076). No significant difference in duration of hospital stay was found between the pravastatin and placebo patients in any diagnostic group. CONCLUSIONS: Pravastatin therapy reduced the burden of hospital admissions for cardiovascular disease, without any adverse effect on noncardiovascular hospitalization.  (+info)

The article reflects on the cholesterol-lowering treatment in adults with the help of pharmacological interventions to reduce morbidity and mortality from atherosclerosis. Topics include reduction of risk of adverse cardiovascular events in chronic kidney disease (CKD) populations with the help of regimens including a statin, association of low density lipoprotein cholesterol (LDL-C) with atherosclerotic events, and association of LDL-C and coronary artery disease in dialysis patients ...
The CDCs National Health and Nutrition Examination Survey results1 highlight recent trends associated with cholesterol-lowering medications. Among adults in the US aged 40 and over during 2003-2012, the percentage using a cholesterol-lowering medication in the past 30 days increased from 20% to 28%. Statin use overall increased from 18% to 26%, and by 2011-2012, 93% of adults who were using a cholesterol-lowering medication used a statin. The use of cholesterol-lowering medications increased with age, with 17% of adults aged 40-59 and 48% of adults aged 75 and over taking them. Cholesterol-lowering medications were used by approximately 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia. Use of cholesterol-lowering medications was more prevalent among adults aged 40-64 with health insurance than those without it. Of prescription cholesterol-lowering medications, the most commonly used product was simvastatin, with 42% reporting its use. Following this was ...
Atorvastatin cholesterol-lowering drug. Box containing tablets of the cholesterol-lowering drug atorvastatin on an ECG (electrocardiogram) readout. Statins are used to lower the levels of low-density lipoprotein (LDL) cholesterol (bad cholesterol) in the bloodstream. High levels of LDL cholesterol (hypercholesterolaemia) are a major cause of heart disease and strokes. Statins work by blocking the effects of the enzyme HMG-CoA reductase, which normally causes the body to produce LDL cholesterol from foods. - Stock Image C026/3783
In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries. The study was published online by the journal PLoS One on December 6, 2011.. The findings support a large clinical study that recently showed patients taking high-doses of the cholesterol-lowering medications not only reduced their cholesterol levels but also reduced the amount of plaque in their arteries. However, until now researchers did not fully understand how statins could reduce atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque in arteries, a major cause of mortality in Western countries. High blood cholesterol is a major culprit in atherosclerosis. As a result of narrowing arteries, blood clots can form or plaque can break off causing blockages in vessels. This can lead to a potentially fatal heart attack or stroke.. Our new research shows statins actually promote the regression of ...
Serum Cholesterol Level and Mortality in U.S. MenandLow Serum Cholesterol and Mortality from Injuries and Suicide. If the 1980s brought a consensus that lowering serum cholesterol reduces ones risk for coronary heart disease, the 1990s have heralded a re-appraisal of the presumed safety of cholesterol-lowering treatments. The possibility that cholesterol reduction may increase mortality from causes other than heart disease began to receive serious attention in 1990 when meta-analyses of cholesterol-lowering trials showed that coronary heart disease benefits may be offset by increased rates of noncoronary heart disease deaths (1, 2). These studies found that cholesterol-lowering treatments were associated, albeit inconsistently, with increased cancer mortality and death from suicides and violence. The absence of preformed hypotheses and biological mechanisms raises suspicion that such findings may be spurious, but the strong design of the clinical trials encourages attribution of increased ...
[101 Pages Report] Check for Discount on Global Cholesterol-Lowering Drugs Market Professional Survey Report 2017 report by QYResearch Group. This report studies Cholesterol-Lowering Drugs in Global market, especially...
Nationwide, less than half of stroke patients discharged from the hospital received a prescription for cholesterol-lowering medications called statins, and the likelihood of a prescription varied by patients geographic location, ...
Health, ...Boston Mass. - A cholesterol-lowering drug reduced the enlarged prost... We dont know the mechanism but the results suggest to us that lower...For unknown reasons about half of men older than 50 (and 80 percent o...The study implicates circulating cholesterol in the progression of the...,Cholesterol-lowering,drug,shrinks,enlarged,prostates,in,hamster,model,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran, an investigational twice-yearly cholesterol-lowering therapy
My mind kept going back to the fact that he had been just fine until he went to the doctor. At first, we would say this to each other as a joke. Gee, sure glad you got yourself to that doctor!, etc. But after a while, the joke didnt seem so funny. I began to wonder if there could be a connection between my husbands issues and the medications he was taking. I looked online and saw many anecdotal accounts of people experiencing muscle weakness with statins, but not with other cholesterol-lowering drugs. However, I remained suspicious. Maybe, I theorized, what constituted a healthy level of cholesterol differed from person to person...just like women have differing levels of hormones. In other words, what was normal for one might not be normal for others. Perhaps there was some kind of individual set-point for cholesterol, and when you got below that set-point for your particular body, nerve health was affected. (This remains just a theory of mine...and has no basis whatsoever in scientific ...
People whose cholesterol improved after one month on cholesterol-lowering drugs called statins reduced their risk of stroke and heart attack...
A cholesterol-lowering drug appears to disrupt sleep patterns of some patients, researchers reported at the American Heart Associations Scientific Sessions 2007.
An FDA panel voted 11-4 to recommend that the agency approve Amgens cholesterol-lowering drug Repatha, though it did express concern over the length of key studies.
Drug discoverer and early stage developer Nyrada (ASX: NYR) has had a significant advance made in the pre-clinical studies of its cholesterol-lowering drug program published in a medical journal.
High cholesterol is simply one of several conditions you could encounter as you age. Keeping your cholesterol degrees within a secure range could need medication. Recognizing the possible effects of high cholesterol therapies can help you understand what to get out of your cholesterol-lowering drug. With many different
Rodrigues, M., et al. Proteolytic hydrolysis of cowpea proteins is able to release peptides with hypocholesterolemic activity. Food Research International. 77(1), 43-48. 20/04/2015.. ...
Study examines the impact of cholesterol-lowering medications on breast cancer recurrence for those receiving adjuvant endocrine therapy.
BACKGROUND: Cholesterol lowering with statins reduces the risk of vascular disease, but uncertainty remains as to whether more intensive statin therapy produces worthwhile benefits safely. Blood homocysteine level is an independent marker of vascular risk, but it is unknown whether this association is causal. METHODS AND RESULTS: 12,064 myocardial infarction survivors have been randomized to more versus less intensive cholesterol-lowering treatment using simvastatin 80 mg versus 20 mg daily. Allocation to more intensive treatment has yielded average further low-density lipoprotein cholesterol reductions of 0.5 mmol/L at 2 months and 0.4 mmol/L at 5 years. In addition, using a factorial design, these patients have been randomized to homocysteine lowering with folic acid 2 mg plus vitamin B12 1 mg daily versus matching placebo, yielding an average 3 to 4 mumol/L reduction in homocysteine. After 6 years of median follow-up, the annual overall rate of major vascular events is approximately 3%. Follow-up is
When it comes to nonadherence of prescription medications, it is often senior citizens who are the subject of the discussion, but the findings of the recent CVS Caremark study point to those under the age of 45. The findings are not only alarming but also important as they further demonstrate the need for healthcare reform and for retail pharmacy to rise to the challenge and be part of the solution.. Unless steps are taken to address the problem of non-adherence, these younger adults will further weigh on an already broken healthcare system because they face an increased risk for developing heart disease, which, in the end, will increase their healthcare costs. As it stands, non-adherence currently costs the United States an estimated $177 billion a year.. CVS Caremark has been vocal on its desire to be on the front lines of health care and clearly recognizes that it is in an ideal position to help with the healthcare solution. In fact, much of its focus has been on adherence programs, disease ...
BACKGROUND:. The Lipid Research Clinics Coronary Primary Prevention Trial and the Coronary Drug Project had shown that morbidity and mortality from ischemic heart disease were reduced by blood cholesterol-lowering therapy. Although blood cholesterol reduction ameliorated experimental atherosclerosis in animal models, the two largest human studies with angiographic observation of arterial lesion change, the NHLBI Type II Coronary Intervention Study and a study by Cohn et al, had not demonstrated significant treatment effects. Favorable, but inconclusive, treatment trends were observed in four unrandomized angiographic trials and one trial too small for evaluation of randomized groups.. The clinical trial was supported by a subproject within a program project grant.. DESIGN NARRATIVE:. CLAS-I was randomized and selectively-blinded. Screening for the trial consisted of five clinic visits, at which baseline data, including angiographic data, were obtained and a prerandomization trial of the study ...
These cholesterol-lowering medications might just be the single worst group of drugs for your brain. Memory loss is now required to be listed as a side effect on the label.. One-quarter of your brain is made up of cholesterol. Cholesterol is necessary for memory, learning, and fast thinking. So it is not a total surprise that cholesterol-lowering drugs negatively effect the brain.. 2.Sleeping pills. The sleeping pills can cause long-term memory loss, but also short-term memory loss. In fact, some researchers found that all sleeping pills are producing some level of impaired memory and performance. Sleeping pills suppress the action potentials of a wide variety of brain cells and reduce our alertness, vigilance, and judgment.. Some sleeping pills can cause a state similar to blacking out that occurs when some person has too much alcohol in the body and cant remember previous situations due to damaged brain cells.. 3.The Anti drugs. The anti-drugs, including antipsychotics, antispasmodics, ...
According to Reuters, a study published in The BMJ suggests that statins and fibrates, popular cholesterol-lowering treatments, may also reduce stroke risk in low-risk patients. Researchers analyzed data gathered from the interviews of 7,500 people who had no risk of vascular disease or stroke. Approximately 27 percent of the people were taking...
Randomized, controlled, single-factor trials of cholesterol-lowering treatment with ≥ 6 months follow-up in which ≥1 death occurred were selected. 35 trials met the selection criteria ...
Health Impact News Comments: While Dr. Peter Osborne does not even address the issue of whether or not it is desireable to lower ones cholesterol, and the
Cholesterol-lowering medication is often the first solution people consider when told that their blood cholesterol level is higher than it should be. However, making smart nutritional choices and
A certain immune reaction is the key, not to slowing atherosclerosis like cholesterol-lowering drugs do, but instead to reversing a disease that gradually blocks arteries to cause heart attacks and strokes. This is the finding of a study in mice led by researchers at NYU Langone Medical Center., A certain immune reaction is the key, not to slowing atherosclerosis like cholesterol-lowering drugs do, but instead to reversing a disease that gradually blocks arteries to cause heart attacks and strokes. This is the finding of a study in mice led by researchers at NYU Langone Medical Center.
Statins, Cholesterol- lowering drugs may be taken by healthy people to reduce the risk of developing heart problems according to a new international study by the American College of Cardiology ...
Preliminary findings did not show that taking the drug reduces the prevalence of significant heart attacks and strokes; at the same time, it did show an increase in side effects to the circulatory and lymph systems, the digestive system, infections, metabolism, the skeletal and muscular systems, the respiratory system and the skin among those taking the prescription medication, the ministry stated ...
This week, the Food and Drug Administration is expected to approve Repatha; several key pieces of housing data will be released; and Mylan shareholders may advance a takeover bid.
Latest News, World , Asia, ASEAN, Singapore,Phillipines, Malaysia , Indonesia, Thailand, Vietnam, Taiwan, Hong Kong,China and India News Headlines. Latest on Sports, Politics, Science and Technology and other things around the globe.
BOSTON, MA -The market for cholesterol-lowering drugs is a multibillion dollar business. With the arrival of new statins, patients are faced with the question…
Despite claims that millions of Americans could be eligible for treatment with a new class of cholesterol-lowering medications, called PCSK9 inhibitors, the fact is these new medicines will supplement - not replace - existing treatment options. PCSK9 inhibitors will help those who cannot be treated with existing cholesterol-lowering medicines.. ...
Each of these six trials effectively broadened the population that could be expected to benefit from cholesterol-lowering therapy. Patients with established CHD had lowered risk of cardiac mortality, but so did patients with no previous evidence of CHD. Patients with very high TC or LDL-C levels benefited from treatment, but so did those with borderline or low levels. When data were analyzed to focus on specific populations, women, younger patients, older patients, and those with diabetes or impaired glucose tolerance, all were consistently found to have reduced coronary event rates. Statin treatment was also shown to be cost effective: the number of patients that had to be treated to prevent one death was quite low, about 30 in the LIPID trial and 33 in the 4S trial. In addition to cardiac death, the range of cardiovascular events or procedures whose incidence was reduced by statin treatment was wide, and included stroke, unstable angina, coronary or carotid revascularization, congestive heart ...
(HealthDay)-Recovery time after surgery may be reduced for patients taking the cholesterol-lowering medications known as statins, according to a new study.
An important new study suggests that statins, the cholesterol-lowering medications that are the most prescribed drugs in the world, may block some of the fitness benefits of exercise, one of the surest ways to improve health.
Could beef eliminate the need for cholesterol-lowering drugs and reduce the incidence of diabetes? Read this patients testimony to learn more.
Now that most cholesterol-lowering drugs (statins) are coming off their patents, it appears that that money train will be ending for those good folks at Big Pharma. As a result it seems that researchers have discovered that the true danger to the heart isnt high cholesterol, after all. Fascinating how these things work, isnt it?
The molecular phenomenon that cholesterol-lowering drugs called statins go through to promote the breakdown of plaque in the arteries has been discovered by researchers.
According to scientists Cholesterol-lowering drugs, known as statins, can reduce the risk of severe infection in patients suffering from heart disease or s
In addition to dramatically reducing the incidence of heart attacks and stroke, the cholesterol-lowering drug Crestor appears to have another important benefit
NEW YORK (Reuters Health) - Cholesterol-lowering drugs are just as effective at preventing heart problems in men and women who have already had a heart attack...
The Canadian Scientists Have Found One More Cause Of Diabetes 2 Types - Part 1 of 3 The Canadian Scientists Have Found One More Cause Of Diabetes 2 Types. Certain statins - the a great extent used cholesterol-lowering drugs - may enlarge your chances of developing type 2 diabetes, a new study suggests in May…
What are PCSK9 Inhibitors? The Food and Drug Administration recently approved two products in a new class of cholesterol-lowering drugs known as PCSK9
Novartis will take a $266 million charge after the drug maker halted the development of an experimental cholesterol-lowering drug, its second setback this week.
A cholesterol-lowering vaccine has shown promise in mice, said researchers Tuesday who announced they had started early-phase trials to see if it also works in humans. Such a treatment could offer a welcome alternative to statins, the main pharmaceutical choice today for lowering cholesterol in people
Greenmedinfo.com - Natural Health Resource - The worlds most widely referenced, open access, natural medicine database, with 30,000+ study abstracts and growing daily
Discussion 1. Golomb cites the following example: For instance, olive oil and corn oil have been used as the placebo in trials of cholesterol-lowering drugs. Under the assumption that these oils might be beneficial, rather than inert, why does this understate the positive benefit of the treatment? 2. Golomb cites another example where a lactose placebo was used in a gastrointestinal trial. Under the assumption that the lactose was harmful, why does this overstate the positive benefit of the treatment? 3. Why is modern communication, e.g., the internet, facebook, etc., a cause for concern when conducting a randomized control trial (with or without a placebo arm)? 4. Golomb further alleges, failure to describe placebo ingredients breaches basic scientific standards of rigor. Why would describing the placebo ingredients disadvantage the publication prospects of the researchers and disadvantage the publisher of the particular journal? 5. Medicine is not the only area of endeavor which ...
Those who propagate for a low-fat diet and cholesterol-lowering drugs claim that there is general agreement about the diet-heart idea.
The cholesterol-lowering drug Vytorin did not help people with heart-valve disease avoid further heart problems but did appear to increase their risk of cancer, scientists reported Monday.
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online 12/01/05 in the JCI, including: Battle of the bulge: Why losing weight is easier than keeping it off for good; The heat is on: Why some cholesterol-lowering drugs cause hot flashes; Age and sex effect ghrelins role in diet-induced obesity; Sweet sixth sense: Glucose-sensing glial cells guard against low blood sugar; and others.
... antilipemic agents MeSH D27.505.954.230.202 - anticholesteremic agents MeSH D27.505.954.230.202.370 - hydroxymethylglutaryl-coa ... antilipemic agents MeSH D27.505.519.186.071.202 - anticholesteremic agents MeSH D27.505.519.186.071.202.370 - ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ...
... antibiotics, antifungals, cytostatics, anticholesteremic, antiparasitics, coccidiostats, animal growth promoters and ... Ansamycins The antitumor agents geldanamycin and macbecin, The antibiotic rifamycin Polyenes The antifungals amphotericin, ... The cholesterol lowering agent lovastatin Discodermolide Aflatoxin Usnic acid Anthracimycin Anthramycin Esterase Nonribosomal ... nystatin and pimaricin Polyethers The antibiotic monensin Tetracyclines The antibiotic agent doxycycline Acetogenins bullatacin ...
Pharmacological Actions : Anti-Inflammatory Agents : CK(4861) : AC(1630), Anticholesteremic Agents : CK(1459) : AC(264) ... 142 Curated Medical Research astracts associated with Anticholesteremic Agents. FRIEND membership. $8 / month $75 / year FRIEND ... Pharmacological Actions : Anticholesteremic Agents : CK(1459) : AC(264), Enzyme Inhibitors : CK(473) : AC(251), HMG-CoA ... PRO MEMBERS get Unlimited Access to downloadable documents like this, with curated research on Anticholesteremic Agents. ...
"Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic ... "Anticholesteremic Agents" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents". ...
Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low- ...
Pravastatin, an antilipemic agent, is used to treat primary hypercholesterolemia. Unlike lovastatin and simvastatin, ...
What is anticholesteremic? Meaning of anticholesteremic medical term. What does anticholesteremic mean? ... Looking for online definition of anticholesteremic in the Medical Dictionary? anticholesteremic explanation free. ... 2. an agent that has this effect.. anticholesteremic. /an·ti·cho·les·ter·emic/ (-kah-les″ter-e´mik) promoting a reduction of ... anticholesteremic. anticholesteremic. [an″te-ko-les″ter-e´mik] 1. promoting a reduction of cholesterol levels in the blood. ...
Anticholesteremic Agents/pharmacology*. *Coronary Disease/prevention & control*. *Humans. Substance. *Anticholesteremic Agents ...
Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Enzyme ...
Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Lipid ... Current use of any other investigational agents. *Women who are pregnant or breastfeeding; pregnant women are excluded from ... this study because simvastatin is a lipid-lowering agent with the potential for teratogenic or abortifacient effects; it is not ...
Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Lipid ...
Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Lipid ...
Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Lipid ... Lipid-lowering agents including fish oils, Cholestin, bile-acid sequestrants, and niacin (,200 mg/day) taken within 6 weeks and ...
Anticholesteremic Agents / adverse effects * Anticholesteremic Agents / therapeutic use* * Apolipoproteins / blood * Biomarkers ...
Anticholesteremic Agents / pharmacology* * Bile Acids and Salts / biosynthesis * Bile Acids and Salts / deficiency* ...
Pharmacological Actions : Anticholesteremic Agents. Additional Keywords : Natural Substance/Drug Synergy. [+] Omega-3 fatty ... Pharmacological Actions : Anti-Inflammatory Agents, Immunomodulatory, Interleukin-6 Downregulation, NF-kappaB Inhibitor, Tumor ...
Anticholesteremic Agents. *MalaCards. *Medline Plus. Pharma. 2282. Antimetabolites. *MalaCards. *Medline Plus. Pharma. 12727. ...
Pharmacological Actions : Anticholesteremic Agents. Problem Substances : Lovastatin. Adverse Pharmacological Actions : ... Pharmacological Actions : Anti-Inflammatory Agents, Antidepressive Agents. Problem Substances : Non-Steroidal Anti-Inflammatory ...
Pharmacological Actions : Anticholesteremic Agents. Problem Substances : Simvastatin. Adverse Pharmacological Actions : ... L-carnitine is a useful therapeutic agent for the treatment of congestive heart failure in combination with traditional ... Pubmed Data : Cardiovasc Hematol Agents Med Chem. 2007 Oct;5(4):295-9. PMID: 17979692 ... reduces the inflammatory milieu in congestive heart failure patients and might serve as a new antiinflammatory agent for the ...
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors From MEDLINE®/PubMed®, a ... Anticholesteremic Agents / chemistry, pharmacology, therapeutic use*. Cholesterol, LDL / blood*, drug effects*. Coronary ... Next Document: Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.. ...
0 (Anticholesteremic Agents); 0 (Apolipoproteins B); 0 (CETP protein, human); 0 (Cholesterol Ester Transfer Proteins); 0 ( ... 0 (Apolipoproteins B); 0 (Apolipoproteins E); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hypolipidemic Agents); 0 ( ...
0 (Anticholesteremic Agents); 0 (Cytostatic Agents); 0 (Cytotoxins); 0 (Microtubule-Associated Proteins); 0 (beta-Cyclodextrins ... Nevertheless, with all agents, these effects translated to the amplified epicardial-to-endocardial and the LV-to-RV non- ... Ga chelating agents can have high influence on physiological properties of Ga labeled bioactive molecules, as was experienced ... 0 (Chemical Warfare Agents); 0 (Cholinesterase Inhibitors); 0 (Gels); 0 (Organophosphorus Compounds); 0 (Organothiophosphorus ...
Anti-Inflammatory Agents / pharmacology, therapeutic use*. Anticholesteremic Agents / therapeutic use*. Arteriosclerosis / drug ... 0/Anti-Inflammatory Agents; 0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 ...
Anticholesteremic Agents · Cholesterol Esters · Esterification · Human · In Vitro · Lipoproteins, LDL · Lipoproteins, VLDL · ... Anticholesteremic Agents; Cholesterol Esters; compactin, 73573-88-3; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin, 75330- ...
Anticholesteremic Agents · Cholesterol Esters · Esterification · Human · In Vitro · Lipoproteins, LDL · Lipoproteins, VLDL · ... Anticholesteremic Agents; Cholesterol Esters; compactin, 73573-88-3; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin, 75330- ... Anti-Inflammatory Agents · Aorta · Apolipoprotein E3 · Apolipoproteins E · Arteriosclerosis · Cell Adhesion · Cholesterol · ... Antiinflammatory agent · Apolipoprotein E · Apolipoprotein E3 (Leidein) · Cytokine · Fluorobenzene · Hydroxymethylglutaryl ...
The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase ( ...
Anticholesteremic Agents Cholecalciferol Cholesterol Kinetics Liver Mevalonic Acid Oxidoreductases Rats Sterols Subcellular ... Studies on the inhibitory mechanism of some hypocholesterolemic agents on 7-dehydrocholesterol delta-7-bond reductase activity ... Studies on the inhibitory mechanism of some hypocholesterolemic agents on 7-dehydrocholesterol delta-7-bond reductase activity ...
An anticholesteremic agent that inhibits sterol biosynthesis in animals.. Vardenafil Dihydrochloride. A piperazine derivative, ... PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION ... If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the ...
An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of ... An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total ... If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the ...
Antineoplastic Agents, HMG-CoA Reductase Inhibitors, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors. ... The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase ( ... The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase ( ... Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent ...
239000003529 anticholesteremic agents Substances 0.000 claims description 16 * 239000003429 antifungal agents Substances 0.000 ... antimicrobial agents; antiviral agents; antifungal agents; antibiotics; chemotherapy agents; antineoplastic/ anti-miotic agents ... antimicrobial agents; antiviral agents; antifungal agents; antibiotics; chemotherapy agents; antineoplastic/ anti-miotic agents ... antimicrobial agents; antiviral agents; antifungal agents; antibiotics; chemotherapy agents; antineoplastic/ anti-miotic agents ...
Antihypertensive Agents. Phase 4. 8. Anticholesteremic Agents. Phase 4. 9. Antimetabolites. Phase 4. ...
  • Alkyl and Aryl Transferases;Anticholesteremic Agents;Astrocytes;Cells, Cultured;Cytokines;Enzyme Induction;Enzyme Inhibitors;Interleukin-1;Interleukin-6;Lipopolysaccharides;Lovastatin;Macrophages;Mevalonic Acid;Microglia;Mitogens;NF-kappa B;Nitric. (musc.edu)
  • The drugs Anticholesteremic Agents and Antimetabolites have been mentioned in the context of this disorder. (malacards.org)
  • Subsequently, 93 patients underwent combined therapy by adding a second agent (simvastatin in a dose of 20 mg/day or fenofibrate in a dose of 200 mg per day) which was continued for another 12 months. (unboundmedicine.com)
  • Pravastatin, an antilipemic agent, is used to treat primary hypercholesterolemia. (pharmacycode.com)
  • An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. (bioportfolio.com)
  • Colemin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. (minclinic.ru)
  • Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
  • An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS. (bioportfolio.com)
  • Studies on the inhibitory mechanism of some hypocholesterolemic agents on 7-dehydrocholesterol delta-7-bond reductase activity. (nextbio.com)
  • The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with 20,000 times greater aff. (nextbio.com)
  • The compound is a potent anticholesteremic agent. (nih.gov)
  • many important medicines have been discovered directly from fungi or developed based on their secondary metabolites [ 1 ], such as the antibiotic penicillin, anti-cholesteremic agent lovastatin, immuno-suppressant cyclosporin A, and the anti-multiple sclerosis fingolimod. (mdpi.com)
  • This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications. (umassmed.edu)
  • Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. (biomedsearch.com)
  • In patients with mixed hyperlipidemia, monotherapy with one of these agents may not be effective and combined treatment may be preferable. (unboundmedicine.com)
  • To compare retrospectively the efficacy and safety of combined statin-fibrate treatment in patients with mixed hyperlipidemia in whom previous monotherapy with one of these agents occurred ineffective. (unboundmedicine.com)
  • AIM: To compare retrospectively the efficacy and safety of combined statin-fibrate treatment in patients with mixed hyperlipidemia in whom previous monotherapy with one of these agents occurred ineffective. (unboundmedicine.com)
  • Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles. (umassmed.edu)
  • This GMI PUB document will greatly reduce your research time due to the Cumulative Knowledge feature, and contains a condensed form of the studies that we have accumulated on Anticholesteremic Agents. (greenmedinfo.com)